

**LungLife AI, Inc.**  
(the "Company" or "LungLife")

**Directorate Change**

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the resignation of James McCullough, as a non-executive director of the company, with effect from 24 October 2024.

James McCullough has taken the decision to step down from the Board to focus on his Executive role at Renalytix plc.

Following this resignation, the Board remains confident in its current composition, which continues to reflect a strong balance of skills, experience, and independence. At this time, the Board has no immediate plans to seek a replacement, as it believes the current structure, together with the Scientific Advisory Board, is well-positioned to support the company's ongoing growth and development and does not impact the composition and independence of our committees.

Roy Davis, Non-Executive Chairman commented "On behalf of the Board I would like to thank James for his significant contribution as Non-executive Director to LungLife AI and wish him all the best in the future. Whilst we will miss his insights, the Board remains strong and independent, supported by our Scientific Advisory Board, and we are confident in our ability to continue delivering on our long-term goals for the business."

**For further information please contact:**

**LungLife AI, Inc.**  
Paul Pagano, CEO  
David Anderson, CFO

[www.lunglifeai.com](http://www.lunglifeai.com)  
via investors@lunglifeai.com

**Investec Bank plc (Nominated Adviser & Broker)**  
Virginia Bull / Lydia Zychowska / Sara Wallace

**Tel: +44 (0)20 7597 5970**

**Goodbody (Joint Broker)**  
Tom Nicholson / Cameron Duncan

**Tel: +44 (0) 20 3841 6202**

**About LungLife**

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit [www.lunglifeai.com](http://www.lunglifeai.com)

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAFLFITISLSFIS